Novel Peptide Rapidly Improves Glucose Tolerance by Targeting Fat Tissue Blood Vessels

Obesity and type 2 diabetes are major global health challenges, often characterized by glucose intolerance and insulin resistance. Current treatments primarily focus on weight loss or direct insulin modulation. However, the specific role of adipose tissue vasculature (blood vessels within fat) in metabolic dysfunction and whether targeting it can improve glucose metabolism independently of weight loss remains underexplored.

Treatment with the peptide significantly improved glucose tolerance in both DIO and ob/ob mice. In DIO mice, glucose excursion during an oral glucose tolerance test (OGTT) was reduced by ~43% compared to controls (p<0.01). This improvement was observed as early as 3 days into treatment and was sustained for the entire 14-day period. The peptide also led to a 2.5-fold increase in insulin sensitivity in DIO mice (p<0.05) and a 1.8-fold increase in ob/ob mice (p<0.05). Furthermore, analysis showed a ~30% reduction in adipose tissue microvessel density (p<0.01) and increased expression of genes related to fatty acid oxidation in muscle. Crucially, these metabolic improvements occurred without any significant change in body weight, food intake, or overall adipose tissue mass, demonstrating a weight-independent mechanism.